Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.46 USD

18.46
485,115

+0.80 (4.53%)

Updated Nov 11, 2024 12:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

by Zacks Equity Research

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use

by Zacks Equity Research

Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.

GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year.

Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.

Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod

by Zacks Equity Research

Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.

Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug

by Zacks Equity Research

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.

Adial (ADIL) Shares Up 43% in the Past Week: Here's Why

by Zacks Equity Research

Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.

Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets

by Zacks Equity Research

Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.

Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Acadia (ACAD) Expands Existing Licensing Deal With Neuren

by Zacks Equity Research

Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.

Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS

by Zacks Equity Research

Acadia (ACAD) is set to begin a pivotal study evaluating a new developmental candidate, ACP-101, in the treatment of hyperphagia associated with Prader-Willi syndrome.

Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates

by Zacks Equity Research

Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.

Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.

Ekta Bagri headshot

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

by Ekta Bagri

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth

by Zacks Equity Research

Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.

Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

by Zacks Equity Research

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

by Zacks Equity Research

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.